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Abstract: Clear cell renal cell carcinoma (ccRCC), the most aggressive and lethal form of renal cell carcinoma acc- 
ounts for over 90% of metastasis that occur following curative surgery for clinically confined disease. High relapse 
rates have prompted the evaluation of targeted therapies for the prevention or delay of metastatic disease in high-
risk patients, with biomarkers offering significant potential to guide and improve patient management in this setting. 
In this current study we examined the value of the 4E-BP1/eIF4E axis for prognostic significance and risk stratifica-
tion in patients with clinically confined ccRCC. This axis is a critical convergence point for many signalling pathways 
that are targeted by current therapies for the treatment of advanced RCC. Immunohistochemistry for phosphory-
lated 4E-BP1 (p4E-BP1) and total eIF4E was performed on tissue microarrays containing tumour cores from 135 
patients with localised ccRCC. For both biomarkers 39% of all evaluable cores stained positive, with a strong cor-
relation observed between the presence of p4E-BP1 and the overexpression of eIF4E within the same tumour (P = 
0.005). Further, the combined expression of p4E-BP1 and eIF4E was associated with significantly worse disease-
free survival of 2.9 vs 5.7 yrs compared to patients whose tumours expressed only one, or neither, of the biomarkers 
(P < 0.001). Cox-regression analysis confirmed the ability of the p4EBP1/eIF4E signature to independently identify 
high-risk patients with a Hazard Ratio of 4.2 (CI = 2.1-8.6; P < 0.001), compared to 3.3 for tumour grade 3 and 4, 
and 2.3 for tumour stage 3 and 4. These data show the powerful prognostic value of the p4E-BP1/eIF4E signature 
for potential management of patients with clinically confined ccRCC, and in addition provides insights into the pos-
sible key synergistic determinants of disease progression and treatment response. 
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Introduction
Renal cell carcinoma (RCC) is a heterogeneous 
and complex family of kidney tumours that are 
comprised of several distinct subtypes of which 
the clear cell subtype (ccRCC) comprises 
70-80% of cases and more than 90% of RCC 
tumour deaths [1]. The incidence of RCC 
appears to be rising steadily at a rate of 2.5% 
per year [2]. These increases reflect the detec-
tion of incidental tumours through improved 
abdominal imaging [3] and the increased prev-
alence of risk factors such as smoking, obesity 
and hypertension [2]. The majority of sporadic 
ccRCC’s arise from loss of function mutations 
or biallelic hypermethylation of the VHL gene 
[4]. At first presentation one-third of all patients 
with RCC will have established metastatic 
tumours (mRCC) and despite the introduction of 
molecular targeted therapies the overall 5 year 
survival rate of this patient group rarely exceeds 
10%. Patients who present with clinically con-
fined disease will usually undergo curative 
nephrectomy, however, up to 40% will eventu-
ally relapse with secondary tumours at distant 
sites. The clinical course in localised ccRCC is 
difficult to predict, even within patients who 
have similar clinico-pathological parameters ie. 
tumour stage and grade, presence of vascular 
and capsular invasion. 
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The identification of molecular signatures that 
accurately reflect biologically relevant path-
ways in RCC should prove valuable for predict-
ing the behaviour of tumours and their response 
to treatment [5]. The incorporation of predictive 
tumour biomarkers in prognostication schemes 
for surveillance purposes and treatment choice 
is increasingly implemented [5, 6]. The number 
of potential tumour biomarkers reported for 
RCC has increased exponentially over the last 
decade but few have proven to have valid clini-
cal utility. Reliable biomarkers which provide 
prognostic or predictive evidence and add fur-
ther value above and beyond conventional his-
tological parameters are still needed to guide 
patient management [7].
In recent years, much interest has focussed on 
the mTOR signalling pathway as a suitable drug 
target for the treatment of advanced cancers, 
particularly for mRCC. Distinct signalling cas-
cades such as the EGFR/ERK, PI3-K/AKT and 
IGFR pathways are known to converge at mTOR 
to modulate cell growth, migration and inva-
sion. The two most studied immediate effector 
molecules of mTOR are the 4E-binding protein 1 
(4E-BP1) and p70SK6, which together comprise 
the TORC1 component of the mTOR signalling 
hub. The mTOR mediated phosphorylation of 
p70SK6 activates the 40S ribosomal S6 kinase 
at serine-235 and serine-236 thereby initiating 
ribosomal biogenesis. Meanwhile, inhibitory 
phosphorylation of 4E-BP1 at serine-65 repre-
sents an important terminal step of a hierar-
chal phosphorylation cascade that reduces the 
ability of 4E-BP1 to bind and inactivate the 
translation-initiation factor eIF4E. Clinical stud-
ies have shown the inactivated phosphorylated 
form of 4E-BP1 (p4E-BP1) to be the most accu-
rate single biomarker of the mTOR pathway for 
the prediction of disease progression in carci-
nomas of the ovary [8], brain [9] and prostate 
[10]. 
At the normal low cellular levels the eIF4E mol-
ecule is a rate-limiting factor governing the 
kinetics of protein synthesis [11]. Under high 
levels of expression such as in cancer cells, 
eIF4E favours the translation of mRNA subsets 
that have complex and highly structured 5-ter-
mini [12]. These proteins often have short-half 
lives and include the oncogenic growth promot-
ing proteins cyclin D1 and c-myc and the anti-
apoptotic molecules survivin and Mcl-1 [11]. 
Functional studies have shown eIF4E to be a 
bone fide oncogene where its forced overex-
pression is sufficient alone to cause cell immor-
talisation and abrogation of apoptosis leading 
to chemo- and radio-resistance in cancer cells 
[13]. For example, in mice the overexpression 
of eIF4E is able to sustain the growth of human 
lymphoma xenographs [14]. While in cancer cell 
lines derived from the prostate [10], breast [15] 
and endometrium [16] the targeted downregu-
lation of eIF4E is shown to induce cell death 
and suppress cell growth and invasion. Con- 
sistent with these pro-oncogenic properties 
elevated levels of total eIF4E are reported in 
many advanced cancers including malignan-
cies of the oesphagus [17], breast [18], liver 
[19] and lung [20]. Phosphorylation of eIF4E at 
residue serine-209 by MAPK-interacting pro-
teins, MNK1 and MNK2, leads to increases in 
protein synthesis and promotes tumorigenesis. 
However, the exact role of phosphorylated 
eIF4E in oncogenic transformation and cancer 
maintenance remains uncertain as tumour lev-
els of phosphorylated eIF4E do not appear to 
correlate with disease progression or other 
aggressive features [11, 21].
This current study was conducted with archival 
primary tumour material from a consecutive 
series of 135 patients diagnosed with ccRCC 
and who had previously undergone presump-
tive curative surgery for localised disease. We 
found that the presence of p4E-BP1 in the pri-
mary tumour correlates in a highly significant 
manner with the over-expression of eIF4E, and 
that both p4E-BP1 and eIF4E serve as indepen-
dent biomarkers for disease recurrence. 
Moreover this biomarker combination identifies 
a subset of patients with aggressive disease 
who exhibit significantly poorer disease free 
survival. Multivariate analysis showed that the 
composite co-variate of p4E-BP1/eIF4E to be a 
powerful predictor of early relapse with a haz-
ard ratio of 4.2 (vs 2.3 for stage pT3 & pT4 and 
3.3 for Grade 3 & 4 disease). We propose that 
p4E-BP1 and eIF4E together represent a bio-
logically relevant molecular signature in ccRCC 
for the prediction of disease progression and 
clinical trial patient stratification which seeks to 
evaluate cognate molecular targeted thera- 
pies.
Materials and methods
Antibodies and reagents 
Rabbit polyclonal antihuman antibodies for 
p4E-BP1 (Ser65) and total eIF4E were pur-
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Table 1. Summary of patient details
Patient breakdown (= 135)
Age (years) Median 63
Min 33
Max 86
Gender Male 89
Female 46
Grade 1 18
2 81
3 25
4 11
T Stage 1 52
2 30
3 & 4 53
Size (cm) < 4 24
4-7 49
7-10 42
> 10 20
chased from New England Biolabs (Herts, UK). 
Swine anti-rabbit secondary HRP-conjugated 
antibodies and non-immune rabbit serum were 
obtained from DAKO (Cambridge, UK). All anti-
bodies and reagents were used according to 
the manufacturer’s instructions.
Patient selection and tissue microarray con-
struction
The patient cohort, previously described in part 
elsewhere [22-24], consisted of a consecutive 
series of 175 patients, who had undergone 
curative radical nephrectomy between 1992 
and 1999 for primary RCC. Paraffin blocks, his-
tology reports and slides were available in all 
cases. Sections were reexamined and the 
tumours re-staged to UICC 2002 and tumour 
type classified according to the WHO 2004 
classification; all tumours classified as clear 
cell renal cell carcinoma (ccRCC) were selected 
for study (135 cases). Also recorded were; 
Fuhrman nuclear grade [25], the presence or 
absence of any vascular invasion (either micro-
vascular invasion, renal vein invasion or inferior 
vena cava invasion) [22], and whether or not 
there was capsular invasion with cellular inva-
sion of peri-nephric or renal sinus fat [26]. The 
ECOG-Performance status of the patients was 
not available. None had received treatment or 
had evidence of lymph node or distant meta-
static disease prior to or at surgery.
Clinical follow-up was carried out as previously 
described [22, 23]. Patients had usually been 
reviewed annually as an out-patient for between 
3-8 years; the following information was 
extracted from the patient records: date of 
birth, gender, date of surgery, date last seen, 
date of death, cause of death and the date on 
which recurrent or metastatic disease was first 
identified. 
For each renal carcinoma a paraffin-embedded 
block was selected that contained a sample of 
peripheral tumour that could be used in the tis-
sue microarray (TMA). A single core of represen-
tative peripheral tumour, 0.6 mm in diameter, 
was punched from each donor block and using 
a specific orientation transplanted into a pre-
moulded recipient paraffin wax block. Additional 
cores were taken from normal renal tissue 
(adjacent to some of the tumours) and from 
human placenta. Serial sections were cut at 4 
µm thickness from the resulting TMA block and 
laid onto clean adhesive glass slides (Super- 
frost PlusTM). 
Immunocytochemistry and staining interpreta-
tion 
TMA sections were deparaffinised and rehy-
drated using standard methodologies as previ-
ously described [23]. Endogenous peroxidase 
activity within the rehydrated tissue was inacti-
vated with 3% hydrogen peroxide in methanol 
for 10 min at room temperature. Antigen 
retrieval was carried out by boiling in sodium 
citrate solution (pH 6.0) for 10 min and then 
cooled and equilibrated in OptimaxTM wash buf-
fer. The TMA sections were incubated (15 hr at 
4°C) with the primary antibodies for eIF4E (dilu-
tion 1:25), and p4E-BP1 (dilution 1:25) with the 
diluent 0.6% BSA in OptimaxTM wash buffer. 
After washing (4 × 1 min), sections were incub- 
ated with the appropriate secondary HRP-
conjugated antibody at a dilution of 1:100 for 1 
hr at room temperature. After washing the sec-
tions were developed using 3,3’-diaminobenzi-
dine (Sigma, Poole, UK) and then counter-
stained with haemotoxylin, dehydrated and 
mounted. Negative controls consisted of sec-
tions where the primary antibody had been 
omitted or replaced with non-immune rabbit 
serum. Positive controls for p4E-BP1 and eIF4E 
immunoreactivity consisted of human placenta 
tissue cores incorporated into the TMA.
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scores were then converted to a sim-
ple binary score of either negative or 
positive according to the most infor-
mative split by Kaplan-Meier analysis. 
Any staining for either eIF4E or p4E-
BP1 was considered positive while a 
complete absence of staining was con-
sidered negative.
Statistical analysis
Correlations between biomarker ex- 
pression and prognostic clinico-patho-
logical variables (tumour stage, grade 
and size; presence or absence of vas-
cular invasion and capsular invasion) 
was examined by crosstabulation and 
chi-squared testing or Fishers exact 
test as appropriate. Univariate analy-
sis of disease free survival (DFS) of 
patients with tumours showing differ-
ent scores of staining for each bio-
marker was carried out by the Kaplan-
Meier method using the log rank sta-
tistical test. The first appearance of a 
metastasis was considered an event. 
Patients last seen alive without metas-
tasis or who died due to other causes 
other than RCC were considered cen-
sored at the date last seen or date of 
death, respectively. Multivariate sur-
vival analysis for p4E-BP1 and eIF4E 
was carried out by Cox regression 
using the Enter or Forward Stepwise 
Figure 1. Representative cores from a TMA of clinically confined clear cell renal cell carcinoma. Images demonstrate 
the negative and positive immunohistochemical staining pattern for p4E-BP1 (A to D) and eIF4E (E to H). Typical 
cores for p4E-BP1 and eIF4E are shown in low (A, B, E, F) and high magnification (C, D, G, H).
Scoring of TMA sections were undertaken by a 
pathologist (DFRG) and research associate (LC) 
using a double-headed light microscope with-
out prior knowledge of clinical outcome as pre-
viously described [23, 24]. Expression of each 
marker was assessed semi-quantitatively ac- 
cording to a previously validated criteria that 
accounted for both the intensity of immuno-
stain and percentage of tumour cells involved 
within each core. Scoring was as follows: 0: no 
detectable deposit in tumour cells; 1: very light 
diffuse or focal light deposit in tumour cell cyto-
plasm; 2: light diffuse or moderate focal depos-
it (but may include very small areas of heavy 
deposit); 3: tumour containing areas of heavy 
deposit in most or all tumour cells. These 
(Likelihood Ratio) function with the covariates 
grade and stage entered in the final model.
The statistical package SPSS 11.5 was used 
for analysis. All tests were two tailed.
Results
Presence of phosphorylated 4E-BP1 correlates 
in a highly significant manner with the overex-
pression of eIF4E in clinically-confined ccRCC 
tumours
A summary of patient details are shown in Table 
1. Of the 135 cases of clinically confined ccRCC 
113 cases were assessable for the measure-
ment of p-4EBP1 stain. Of these 43 (38%) 
Table 2. Relationship of p4E-BP1, EIF4E, and combined 
p4E-BP1/EIF4E with clinico-pathological parameters in 
clinically confined ccRCC
p4E-BP1  
(n = 113)
EIF4E  
(n = 129)
Combined  
(n = 111)
Grade -ve +ve -ve +ve -ve +ve
    Grade 1 & 2 56 29 62 33 71 12
    Grade 3 11 8 13 10 14 5
    Grade 4 3 6 6 5 5 4
P = 0.15 P = 0.62 P = 0.062
Size 
    4 cm and less 11 7 16 6 14 2
    > 4 cm to 7 cm 24 16 27 20 31 9
    > 7 to 10 cm 26 11 26 14 31 6
    > 10 cm 9 9 12 8 14 4
P = 0.52 P = 0.65 P = 0.78
Stage
    Stage 1 26 15 31 19 33 6
    Stage 2 14 10 21 7 20 4
    Stage 3 & 4 30 18 29 22 37 11
P = 0.27 P = 0.27 P = 0.63
Vascular Invasion
    (-ve) 40 23 48 25 53 8
    (+ve) 30 20 33 23 37 13
P = 1 P = 0.42 P = 0.08
Capsular Invasion
    (-ve) 56 34 66 39 72 16
   (+ve) 14 9 15 9 18 5
P = 0.9 P = 0.98 P = 0.70
P < 0.05 denotes significance.
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Figure 2. Kaplan-Meier disease-free survival plots of patients presenting with clinically confined ccRCC whose pri-
mary tumours were stratified as positive (+) or negative (-) for expression of p4E-BP1 (A), eIF4E (B), co-expression of 
p4E-BP1 and eIF4E (C), and sub-analysis (D) of patients who were either negative for both p4E-BP1 and eIF4E; posi-
tive for p4E-BP1 alone; positive for eIF4E alone; positive for both biomarkers. Patients whose tumours expressed 
both p4E-BP1 and eIF4E had significantly worse prognosis.
stained positively for p-4EBP1 with: 33 cases 
scored at 1, 9 cases scored at 2, and 1 case 
scored at 3. Similarly for eIF4E 129 cases were 
assessable for the measurement of stain with 
48 (37%) cases staining positively for eIF4E 
with of these: 28 cases scored at 1, 18 cases 
scored at 2, and 2 cases scored 3. Typical 
cores showing positive and negative staining 
for p4E-BP1 and eIF4E are shown in Figure 1. 
The intra-tumoural co-expression of p4E-BP1 
and eIF4E could be assessed in 111 cases with 
21 (19%) of these tumours positively express-
ing both biomarkers (Table 2). Cross-tabulation 
of p4E-BP1 with eIF4E showed a highly signifi-
cant correlation with the p4E-BP1 positive 
staining indicating a statistically significant (P = 
0.005) increased likelihood of eIF4E over-
expression. These data suggest that the phos-
phorylation of 4E-BP1 in ccRCC tumours is a 
distinct biological event that can functionally 
lead to the over-expression of eIF4E.
Lack of association of p4E-BP1 and eIF4E 
with conventional histological parameters of 
clinically-confined ccRCC 
Cross-tabulation of p4E-BP1 and eIF4E as indi-
vidual biomarkers, or as a combined co-variate, 
failed to demonstrate any significant associa-
tion with conventional clinico-pathological 
parameters (Table 2). A strong trend for the 
combined expression of p4E-BP1 and eIF4E 
with high tumour grade was however observed 
(P = 0.062). This data suggests that the prese- 
nce of one or both p4E-BP1 and eIF4E can 
occur as an early event in the pathogenesis of 
ccRCC and is not necessarily secondary to any 
specific aggressive histological parameter.
Tumour expression of p4E-BP1 and/or eIF4E 
leads to poor disease-free survival in patients 
with clinically-confined ccRCC 
Univariate survival analysis showed that 
patients whose tumours stained positive for 
p4E-BP1 had significantly shorter time to 
relapse, with a mean disease-free survival 
(DFS) of 4.4 vs 5.6 yrs compared to patients 
whose tumours were negative (P = 0.02) (Figure 
2A). Similarly, patients whose tumours ex- 
pressed eIF4E had a mean DFS of 4.4 vs 5.7 
yrs compared to patients whose tumours were 
negative (P = 0.005) (Figure 2B). Patients wh- 
ose tumours co-expressed p4E-BP1 and eIF4E 
had a significantly worse mean DFS of 2.9 vs 
5.7 yrs compared to patients whose tumours 
expressed only one, or neither, of the biomark-
ers (P < 0.001) (Figure 2C). 
To assess the influence of p4E-BP1 and eIF4E 
interaction on disease progression an analysis 
was carried out stratifying patients into four 
groups according to combination of expression 
of biomarkers p4E-BP1 and eIF4E (Figure 2D). 
This stratification revealed patients whose 
tumours showed no expression of both p4E-
BP1 and eIF4E (double negative cases, n = 49) 
to have a mean DFS of 5.4 yrs. This DFS was 
similar to that of patients whose tumours 
expressed either p4E-BP1 or eIF4E alone (i.e. 
single positive cases n = 22, DFS 5.6, and n = 
19 DFS 5.3, respectively). However, tumours 
that expressed both biomarkers (double posi-
tive cases) had a significantly worse (P = 0.02) 
DFS of 2.9 yrs. Thus the influence of each bio-
marker on the outcome appeared to be due to 
the inclusion of double positive cases in the 
group suggesting the phosphorylation of 
4E-BP1 and the overexpression eIF4E are 
linked molecular events that co-operate to 
drive disease progression in clinically-confined 
ccRCC.
Cox-regression analyses was undertaken to 
determine the prognostic value of p4E-BP1 and 
eIF4E, either as single co-variates or as a com-
posite covariate together with tumour stage 
and grade. We found p4E-BP1 and p4E-BP1 
and eIF4E were both significant predictors of 
shortened DFS with (Tables 3-5). Notably, the 
composite co-variate of p4E-BP1 and eIF4E 
was a significant and powerful predictor of dis-
ease recurrence (Table 5) with a HR of 4.2 (CI = 
2.1-8.6; P < 0.001), whereas the HR for tumour 
grade was 3.3 (CI = 2.0-5.2; P < 0.001) and for 
stage III and IV was = 2.3 (CI = 2.3-3.6; P < 
0.001).
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Table 3. Multivariate Cox regression hazard 
model for time to recurrence for p4E-BP1 as cal-
culated by Cox proportional hazard computation 
including tumour grade and tumour stage
Prognostic indice HR 95% CI P value
Grade 1 and 2 1
Grade 3 and 4 3.5 2.1-5.6 < 0.001
Stage I and II 1
Stage III and IV 2.3 1.4-3.6 < 0.001
p4E-BP1 covariate negative 1
p4E-BP1 covariate positive 2.3 1.2-4.3 0.01
P < 0.05 denotes significance.
Discussion
Relapse rates for clinically confined RCC are 
frequently reported at 25% to 40% with the abil-
ity to accurately identify patients at high-risk of 
metastatic disease remaining a major chal-
lenge. Conventional clinico-pathological param-
eters appear not to offer a sufficiently discrimi-
native approach and as a result significant 
research has been dedicated toward identify-
ing bio-markers to guide post-operative surveil-
lance in patients having undergone potential 
curative surgery. While prognostic models that 
combine the use of conventional histological 
parameters and circulating or tumour based 
biomarkers have been explored in RCC [27], to 
date none have been prospectively tested for 
routine clinical use. 
In this current work we show both p4E-BP1 and 
eIF4E to be independent influential prognosti-
cators when analysed as individual biomarkers. 
More meaningfully we show a significant asso-
ciation between the presence of p4E-BP1 and 
the over-expression of eIF4E in clinically con-
fined renal tumours of clear cell histology. The 
direct nature of this association may be cor-
roborated by similar findings in other tumour 
types [10, 28] and by contrast to the lack of co- 
rrelation between eIF4E and another down-
stream molecule, pS6, from the mTOR pathway 
[24]. Specifically, using the same archived 
patient cohort we have previously reported [24] 
a lack of correlation between pS6 and the over-
expression of eIF4E (P = 0.342). We also found 
in this present work neither p4E-BP1 or eIF4E 
alone, or their combined expression, correlated 
with any specific clinico-pathological parameter 
for RCC. However, multi-variate analysis dem-
onstrated the combined molecular signature of 
p4E-BP1/eIF4E to be at least as powerful as 
either high tumour grade or high tumour stage 
for predicting the onset of metastatic disease. 
Collectively, these findings provide compelling 
evidence that both p4E-BP1 and eIF4E are 
important functionally-linked determinants of 
early relapse in ccRCC that are able to identify 
aggressive disease in a subset of patients, as 
determined by their significantly shorter DFS. 
Further, the combined expression of p4E-BP1/
eIF4E was able to identify a sub-population of 
patients that displayed low grade/low stage 
disease but were associated with a high risk of 
relapse.
We have previously shown the expression of 
p4E-BP1 to be significantly associated with clin-
ically confined papillary renal cell carcinoma, a 
relatively indolent renal tumour subtype where 
the reported incidence of relapse is much less 
than for ccRCC [24]. Reasons for the increased 
prognostic power of p4E-BP1 in renal tumours 
of clear cell histology most probably reflect 
other molecular alterations that operate in a 
concerted manner to drive disease progres-
sion. Such candidates may include the in- 
creased over-expression of eIF4E, the rate lim-
iting step in protein translation, and the loss of 
functional VHL. Indeed, it has recently been 
shown in RCC cell lines that VHL can directly 
bind pre-40S ribosomal subunits to inhibit ribo-
some biogenesis and repress global protein 
synthesis [29]. Therefore, the presence of p4E-
BP1, coupled with synergistic over-expression 
of eIF4E on a VHL mutated genetic background 
would provide all the necessary machinery for 
enhanced global protein translation to rapidly 
drive the progression in ccRCC as reported in 
this current study.
Table 4. Multivariate Cox regression hazard 
model for time to recurrence for eif4e as 
calculated by Cox proportional hazard compu-
tation including tumour grade, tumour stage 
and tumour size
Prognostic indice HR 95% CI P value
Grade 1 and 2 1
Grade 3 and 4 3.7 2.4-5.6 < 0.001
Stage I and II 1
Stage III and IV 2.0 1.4-2.9 < 0.001
eIF4E covariate negative 1
eIF4E covariate positive 2.3 1.3-4.1 0.006
P < 0.05 denotes significance.
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It has been suggested that cancer cells in gen-
eral which over-express eIF4E are more depen-
dent upon eIF4E than cancer cells driven by 
other oncogenes and that this dependence rep-
resents an “Achilles heel” [30]. In other tumour 
types the overexpression of eIF4E has been 
shown to be dependent upon the presence 
and/or phosphorylation status of p4E-BP1 [10, 
28, 31], the exact molecular mechanism 
responsible for the over-expression of eIF4E in 
RCC is currently unknown. One likely pathway is 
an interaction between eIF4E and c-myc, the 
latter a molecule known to overexpressed in 
advanced RCC [32, 33]. Therefore, increased 
phosphorylation of 4E-BP1 in renal cancer cells 
will result in the release of eIF4E from its inhibi-
tory conformation leading to the production of 
oncogenic proteins, which include amongst oth-
ers c-myc. It is known that the eIF4E gene pro-
moter contains two canonical c-myc response 
elements that are responsive to transcriptional 
activation by c-myc in a number of different 
screens [34]. Any newly formed c-myc therefore 
has the ability to further potentiate the activa-
tion of the eIF4E gene in a positive regulatory 
feedback loop leading to increasing levels of 
eIF4E driving disease progression.
Although molecular targeted therapies such as 
the tyrosine kinase inhibitors (TKIs) e.g. suni-
tinib or pazopanib, mTOR inhibitors e.g. temsi-
rolimus, or VEGF antibodies e.g. bevacizumab, 
have significantly improved survival rates for 
mRCC, not all patients respond favourably and 
of those that do, drug resistance eventually 
develops. Molecular pathology is positioned for 
the discovery and development of tumour bio-
markers that are able to predict and monitor 
treatment response in patients. Indeed the use 
of combined biomarkers is shown to have 
greater value than individual biomarkers alone 
for the prediction of treatment response as well 
as prognostication in a number of different can-
cer types, particularly where the biomarkers 
reflect an intrinsic biologically relevant mecha-
nism or pathway [1]. The p4E-BP1/eIF4E axis 
we describe in this current study represents a 
critical convergence point for several upstream 
signalling pathways such as the EGF-R/ERK 
and AKT/mTOR, all of which are targeted in 
some respect by molecular-targeted therapies 
used in the treatment of renal tumours. 
Phosphorylated 4E-BP1 has recently been 
shown to be the single most accurate bio-mark-
er of the mTOR pathway for predicting treat-
ment response in patients with mRCC treated 
with mTOR inhibitors [35]. However, the above 
study did not include a sub-analysis of patient 
eIF4E status which, we propose from our pres-
ent work would further improve patient discrim-
ination toward treatment stratification options 
for molecular targeted therapies. This conjec-
ture is further supported by recent pre-clinical 
studies in renal cancer cells isolated from in 
vivo tumour models showing that the 4E-BP1/
eIF4E axis to be the principal driver of VEGF-A 
production [36]. 
In summary, we show that both p4E-BP1 and 
eIF4E overexpression demonstrates synergy in 
driving the patho-biology of renal tumours of 
clear cell origin and when assessed together 
can accurately predict early relapse in patients 
with clinically confined disease. Specifically, we 
show that the combined expression of p4E-BP1 
and eIF4E is a biologically relevant biomarker 
combination that has equal or superior prog-
nostic value than current conventional histo-
logical parameters. We propose that the 
assessed combined expression of p4E-BP1 
and eIF4E will have potential to guide and 
improve patient management with respect to 
post-operative surveillance and the instigation 
of targeted therapies. Given that p4E-BP1 and 
eIF4E are important linked determinants of 
early relapse in ccRCC, the targeting of the 
4E-BP1/eIF4E axis in combination with either 
cytokine or targeted therapies to prevent or 
delay relapse appears a rational therapeutic 
approach [37]. Further examination of the p4E-
BP1/eIF4E signature in other patients cohorts 
is warranted, particularly those having received 
molecular targeted therapies.
Table 5. Multivariate Cox regression hazard model 
for time to recurrence for the composite covariate 
of eIF4E and p4E-BP1
Prognostic indice HR 95% CI P value
Grade 1 and 2 1
Grade 3 and 4 3.3 2.0-5.2 < 0.001
Stage I and II 1
Stage III and IV 2.3 2.3-3.6 < 0.001
eIF4E-p4E-BP1 covariate negative 1
eIF4E-p4E-BP1 covariate positive 4.2 2.1-8.6 < 0.001
Tumour size and vascular invasion were also entered into the 
model but were not considered significant at this step. P < 
0.05 denotes significance.
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